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Other countries may also have the objective 
of allocating resources according to a societal 
perspective but despite this choose to exclude 
the costs of added life years.
When making decisions on reimbursements 
TLV in Sweden has three ethical guidelines 
to follow: the human value principle, the 
need and solidarity principle, and the cost‑ef‑
fectiveness principle [9]. The first principle 
says that the health care system should re‑
spect the equal value of each individual. The 
second principle states that the individuals 
with the largest medical needs should be 
allocated more resources than other patient 
groups. The last principle explains that costs 
due to the use of a drug should be reasonable 
from the medical, humanitarian, and societal 
perspective.
The aim of this article is to, from a theoretical 
and empirical point of view, critically analyze 
the Swedish recommendations used by TLV, 
when it comes to the use of costs of added life 
years in economic evaluations of health care. 
The aim is furthermore to analyze the num‑
bers used in Sweden and discuss their impact 
INTRODUCTION
Health economic evaluations are used in 
order to inform decision makers in health 
care and to ensure that limited health care 
resources are used effectively. It is of great 
importance to include the appropriate costs 
and outcomes when evaluating a health in‑
tervention or a specific pharmaceutical. The‑
refore there has been numerous debates on 
what costs and effects to include and further‑
more on what perspective to use [1,2]. One 
much‑debated cost is the cost of added life 
years [3‑7], sometimes referred to as sur‑
vival costs or future unrelated costs among 
others. Costs of added life years refer to the 
net consumption (consumption subtracted by 
production) during the extra years that an in‑
dividual lives due to a lifesaving intervention 
or drug. Sweden is the only country where 
the national guidelines of decisions on reim‑
bursement explicitly state that these costs 
should be accounted for when presenting he‑
alth economic evaluations. These guidelines 
are developed and used by the Dental and 
Pharmaceutical Benefits Agency (TLV) [8]. 
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ABSTRACT
It is of importance to include the appropriate costs and outcomes when evaluating a health intervention. Sweden is the only 
country where the national guidelines of decisions on reimbursement explicitly state that costs of added life years should be 
accounted for when presenting health economic evaluations. The aim of this article is to, from a theoretical and empirical 
point of view, critically analyze the Swedish recommendations used by the Dental and Pharmaceutical Benefits Agency 
(TLV), when it comes to the use of costs of added life years in economic evaluations of health care. The aim is furthermore 
to analyze the numbers used in Sweden and discuss their impact on the incremental cost‑effectiveness ratios of assessed 
technologies. If following a societal perspective, based on welfare economics, there is strong support for the inclusion of 
costs of added life years in health economic evaluations. These costs have a large impact on the results. However this fact 
may be in conflict with ethical concerns of allocation of health care resources, such as favoring the younger part of the 
population over the older. It is important that the estimates of production and consumption reflect the true societal values, 
which is not the case with the values used in Sweden.
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on the incremental cost‑effectiveness ratios 
of assessed technologies.
The outline of the article is as follows; first 
the theoretical viewpoints of including or 
excluding costs of added life years are briefly 
presented. Thereafter, the present numbers 
on production subtracted by consumption 
that are used by TLV in Sweden are presen‑
ted and explained. Moreover, the impact on 
the analysis and the decision of reimburse‑
ment done by the board at TLV is analyzed 
by using two pharmaceuticals. In addition, 
ethical viewpoints are discussed in relation to 
the inclusion of costs of added life years. All 
values are presented in US dollars where $1 
= SEK6.94 (06‑23‑2013).
BACKGROUND
Cost of added life years
The background for the debate on whether 
or not to include costs of added life years is 
founded on the different theoretical views 
that exist. If following a straightforward 
welfarist view, the outcome of an economic 
evaluations should be utilities and to be able 
to reach an optimal resource allocation of he‑
alth the expected utility function of an indivi‑
dual should be maximized, as in the fashion 
of Meltzer [4]. Generally quality‑adjusted 
life‑years (QALYs) are the preferable out‑
come measure and it is intended to represent 
individuals’ utilities. The inclusion of costs 
of added life years is then justified by explai‑
ning that the utility of future expenditures 
due to prolonged life of the patient is inclu‑
ded in the expected utility function, thereby 
a factor that the individual takes into account 
when answering questions related to QALY 
weights, and therefore the costs of these fu‑
ture expenditures should also be included in 
an analysis. Garber and Phelps [3] also use an 
expected utility function but arrive at a diffe‑
rent result than Meltzer [4]. Instead of letting 
survival probabilities of an individual be af‑
fected by all medical interventions during a 
lifetime, Garber and Phelps [3] only let me‑
dical expenditure in the first period affect the 
survival probability in the second period and 
leaving the third period’s survival probability 
unaffected. This leads to their conclusion of 
costs of added life years being equivalent to 
adding a constant in an analysis and thereby 
them not supporting the inclusion of costs 
of added life years. If, on the other hand, an 
extra‑welfarist approach is the basis of an 
analysis the QALYs should be interpreted as, 
not utilities, but as health or as capabilities, 
as Sen [10] advocates. If interpreting QALYs 
as being health or as capabilities the inclu‑
sion of costs of added life years in an analysis 
is not straightforward anymore and utilities 
should be based on, not consumption of go‑
ods or services, but something else.
However, even if welfarism is accepted as the 
general underlying theory, there is an empiri‑
cal question whether measured QALYs fulfill 
the criteria of representing individuals’ utili‑
ties, where studies have shown that this is not 
the case [11]. Even if there exists a common 
consensus that QALYs are not simply utilities 
and should not be interpreted as such, there 
still are disagreements about what is measu‑
red when constructing QALYs and what in‑
dividuals take into account when answering 
questionnaires constructed to produce QALY 
weights. According to Nyman [5] the QALY 
weights are not constructed so that they in‑
clude future consumption and production but 
if they were constructed in this manner the 
costs of added life years should be included 
in an analysis. This aspect has been tested in 
several studies [12‑15] but it is nevertheless 
hard to come to a conclusion. Even though 
the majority does not appear to consider their 
economic situation when answering direct 
methods to elicit QALY‑weights, it does not 
necessarily mean that income does not af‑
fect QALY‑weights. It is probably the case 
that most of the respondents assume similar 
consumption levels as before the change in 
health state. Lundin and Ramsberg [16] fur‑
thermore argue that if QALYs do not measure 
total utility, where utility from consumption 
is not included, a large part of consumption 
expenditures should still be included in the 
analysis since they are necessary to stay alive 
and live a normal functioning life. Gandjour 
[17] also supports the inclusion of costs of 
added life years due to the fact that the indivi‑
dual receives utility from basic needs such as 
food and housing when the life of the patient 
is extended and therefore the costs should be 
included. Recently van Baal et al. [7] argued 
strongly for the inclusion of indirect medical 
costs in economic evaluations .
The recommendation on cost 
of added life years in Sweden
Often guidelines state that a societal perspec‑
tive should be used in economic evaluations, 
meaning all costs and effects should be in‑
cluded, but often there is no common agree‑
ment as to what these costs and effects are. In 
addition, the terms “related” and “unrelated” 
are often difficult to disentangle leading to a 
wide spread of interpretations. Grima et al. 
[18] highlight this difficulty in their article on 
dialysis for chronic kidney disease patients. 
They state that there are large inconsisten‑
ces in CEAs due to the fact that there is not 
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a common understanding to what related and 
unrelated costs are. The Dental and Pharma‑
ceutical Benefits Agency (TLV) in Sweden 
chooses a strict societal perspective, and a 
welfarist approach, by including all costs and 
effects of an intervention or a drug, also the 
unrelated non‑medical ones. This leads to 
their guideline about costs of added life ye‑
ars: «If the treatment affects survival, then 
the costs for increased survival – total con‑
sumption less total production during gained 
life years – should be included» [8]. The in‑
clusion could lead to a decision of reimburse‑
ment being accepted or rejected i.e. the costs 
having a large impact. The inclusion could 
also be in conflict with the other principles 
in the ethical platform that TLV should take 
into consideration when making decisions on 
reimbursement.
The decision to reimburse pharmaceuticals in 
Sweden is done by the board at TLV. Their 
goal is to, through a societal perspective, 
evaluate all costs and benefits of a certain 
medical technology, where all costs also me‑
ans the inclusion of costs of added life years. 
When these costs are included in an analysis 
the numbers that should be used according to 
TLV are calculated in a thesis by Ekman [19], 
but these numbers have not been presented in 
a peer‑reviewed journal. The numbers are a 
summary of consumption and production by 
age from 1997 and are then adjusted by con‑
sumer price index (CPI). The whole table can 
be seen below.
Production is calculated as total labor cost of 
the employee from the employer’s point of 
view. Health care consists of pharmaceutical 
expenditures, which are the per capita sales 
of prescription pharmaceuticals, primary 
and hospital care are from southern Sweden 
and these numbers are used as representati‑
ve numbers for the rest of the country, and 
dental care numbers are only for the dental 
care that is not privately provided. The social 
services costs are collected from the Swedish 
Association of Local Authorities and Stati‑
stics Sweden. Considering the costs of edu‑
cation no detailed information was found in 
the university education part and therefore 
the assumption was made that the intensity 
of study and cost of study was the same for 
younger and older students. Also, the lack 
of information led to an assumption that in‑
dividuals 65 years and older do not partici‑
pate in the adult school education. Data on 
public consumption has been collected from 
Statistics Sweden and data on other private 
consumption consists of elderly care fees and 
Type of consumption
Age
0-19 20-34 35-49 50-64 65-74 75-84 85+ All
Health care
Pharmaceuticals 78 115 194 349 502 569 479 234
Primary and hospital care 653 814 1,010 1,411 2,238 3,090 3,306 1,247
Dental care 121 156 186 202 199 194 192 169
Total 852 1,085 1,391 1,963 2,939 3,852 3,977 1,650
Social services
Elderly care 0 0 0 0 1,035 6,439 21,111 971
Services to impaired people 302 486 486 486 102 102 102 375
Transportation services 6 6 6 6 38 103 288 21
Total 308 492 492 492 1,176 6,645 21,501 1,367
Education
Schools and child care 7,199 0 0 0 0 0 0 1,755
Universities 58 1,192 224 41 2 0 0 310
Adult schooling 18 276 111 15 0 0 0 84
Labor market training 8 98 70 54 0 0 0 45
Total 7,277 1,566 404 110 2 0 0 2,195
General public consumption 2,641 2,641 2,641 2,641 2,641 2,641 2,641 2,641
Other private consumption 8,128 12,579 11,631 15,265 13,764 10,362 7,092 11,613
Total consumption 19,206 18,363 16,560 20,472 20,522 23,499 35,212 19,466
Total production 396 21,346 32,726 29,118 1,311 149 24 16,307
Consumption-Production 18,810 -2,982 -16,165 -8,646 19,210 23,350 35,187 3,159
Table I. Costs of added life years in Sweden in 1997 US dollars (USD1 = SEK6.94) (modified from Ekman, 2002 [19])
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disposable incomes for the elderly, data from 
the family expenditure survey as well as pri‑
vate health care expenditures. [19]
ANALYSIS OF THE NUMBERS
The estimates used today when making deci‑
sions about reimbursement are dated and may 
not be truthful estimates of the consumption 
and production of the population. Due to the 
fact that these estimates can have an impact 
on the decisions of reimbursement they need 
to be critically analyzed. One problem with 
these estimates is for example the fact that 
the estimates for production for 65 year olds 
and older are extremely low and does it really 
make sense that 65 to 74 year olds only pro‑
duce $1,311 worth every year? There seems 
to be a lack of formal production for 65 to 
74 year olds. Also, one important aspect not 
considered in the current estimates is the in‑
formal production of the whole population, 
but most importantly the informal production 
of the population 75 years and older. Fur‑
thermore, the estimates are recommended by 
TLV to be adjusted to today’s numbers throu‑
gh CPI, which may or may not be the right 
method.
The exclusion of informal production from 
these numbers will most certainly lead to fa‑
voring of the younger due to the fact that pro‑
duction in the formal sense will decrease as 
the individual gets older. The informal pro‑
duction in all is hard to get ahold of but there 
are some good estimates of the magnitude. In 
a study presented by Jegermalm and Jepps‑
son Grassman [20] the aspect of informal 
production in Sweden is tackled. The group 
that produces the most in this sector is wo‑
men 75 years and older who spend 60 hours 
per month on these activities, and men spend 
two‑thirds of the time on informal production 
that women do. These activities include tran‑
sportation, other’s household work, looking 
after others in the society, from the young to 
the old and spending time with them. The‑
re is an increase in the informal production 
of elderly from 1992 to 2005 and the largest 
increase is in the care of others, those who 
are not relatives, where the number has in‑
creased from 28 percent to 50 percent in the 
years observed. [20] The inclusion of infor‑
mal production in costs of added life years 
is supported by Meltzer [4]. He wanted to 
integrate leisure, meaning actual leisure and 
informal production, in the utility function. 
This would be done in order to not prioritize 
the younger population and to show a truthful 
estimation of the costs.
Moreover, an additional aspect that has chan‑
ged from the year when the current estimates 
were calculated is the formal production pro‑
duced by the elderly. A study from Statistics 
Sweden shows that 65 and 66 year olds that 
are in the labor force has increased in Swe‑
den since 2001, from not even five percent to 
22 percent in 2009 [21]. One of the reasons 
for this is a change in the law of employment 
protection that took place in 2001 and made 
it possible for employers to work until the 
month they turn 67. Another aspect when 
considering changes to the present estimates 
on production is the fact that there most pro‑
bably will be an increase in the pension age. 
This would lead to even larger differences in 
productivity between reality and the current 
estimates of productivity and would create an 
even larger bias. In the current numbers the 
age group of 65 to 74 year olds has an esti‑
mate of productivity of $1311 per capita per 
year and this would clearly be much higher 
if, and when, the pension age will be increa‑
sed, and would lead to an even larger need for 
new estimates for costs of added life years.
RE‑ESTIMATION OF PRODUCTION
It is necessary to update all the estimates 
used today and below two examples of these 
updates are presented. As stated above, the 
productivity of 65 and 66 year olds has in‑
creased, as well as for older individuals. In 
Sweden in 2011, 13.4 percent of 65‑74 year 
olds were employed [21]. Approximating 
this production and re‑estimating the current 
estimates was done with a recalculation. The 
new productivity for 65‑74 year olds in 2011 
SEK was calculated to be $10.280, compa‑
red to the earlier estimate of $1311. Keeping 
consumption constant and subtracting con‑
sumption by production the new cost of ad‑
ded life years for the age group of 65‑74 year 
olds is $12,362 in 2011 dollars, reducing the 
costs by approximately $10,800 (47%) com‑
pared to the current numbers.
To calculate the accurate total informal pro‑
duction of the elderly would be an almost 
impossible task due to the lack of data but 
estimations can be done to show the impor‑
tance of informal production. It is of course 
the case that the younger population also 
produces informally but the age group 75‑84 
was chosen to show the importance of adding 
informal production in the present estimates 
as well as giving a more truthful estimate of 
production for elderly who do not produce 
formally any longer. As stated before, women 
over 75 years and older spend on average 60 
hours a month on informal production and 
men two‑thirds of what women do [20]. It is 
difficult to estimate the value of this informal 
production because there is no monetary va‑
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lue attached to it and the intensity and quality 
of the informal production varies between 
people of different ages and otherwise. Fol‑
lowing welfare economics, the cost represent 
the best alternative use of the resource, which 
for person in this age group generally is leisu‑
re time. The value of leisure is hard to estima‑
te, but it is not zero. Another way to estimate 
the cost of informal production is by finding 
its replacement cost, that is, the cost of hiring 
a professional to do the same job. In the latter 
case, one has to adjust for effectiveness and 
quality of a professional. In this example, a 
value of 50% of the employer’s cost of using 
a professional health care assistant cost was 
used, which in Sweden in 2012 was $12.68 
per hour. This cost was then multiplied with 
the average hours spent on informal produc‑
tion. To avoid overestimation the age group 
was not allocated any additional production 
apart from the existing numbers. After calcu‑
lations the yearly average informal produc‑
tion of 75 to 84 year olds was found to be 
$12,731 in 2011 dollars. Replacing the cur‑
rent numbers for production of this age group 
and keeping consumption constant the new 
costs of added life years is $15,632, instead 
of $28,183 (Table II).
Another example illustrating how con‑
sumption can change from year to year 
shows the importance of updated numbers. 
In order to account for the fact that when 
years go by the prices differ TLV uses CPI 
to adjust the estimates from 1997 to today’s 
numbers. But this methodology does not ne‑
cessarily represent the rightful increase of the 
estimates. The per capita cost of pharmaceu‑
ticals, according to the present estimates, was 
in 1997 on average $234. By adjusting $234 
with the CPI between 1997 and 2012 the cost 
for pharmaceuticals should be $285 per capi‑
ta in 2012. Studying statistics from 2012 [22] 
shows that the costs of pharmaceuticals per 
capita on average was $382 in 2012 equaling 
a difference of $97 between the real num‑
ber for 2012 and the CPI adjusted number 
for 2012, an increase with 34 percent. This 
example shows that the present numbers are 
underestimating the cost of pharmaceuticals 
65-74 year olds 75-84 year olds
CAL current 
numbers (USD)
CAL updated formal 
production (USD)
CAL current 
numbers (USD)
CAL updated informal 
production (USD)
Consumption 24,770 24,770 28,363 28,363
Production 1,582 12,408 180 12,731
Cost of added life years 23,188 12,362 28,183 15,632
Table II. Example of re-estimated values for certain ages. Increased formal production for 65-74 year olds and informal production for 
75-84 year olds in 2011 US dollars (USD1 = SEK6.94)
CAL = cost of added life years
per capita and this could be the case for the 
other estimates as well.
IMPACT ON THE EVALUATION
Two recent economic evaluations of pharma‑
ceutical drugs are used as examples to show 
the impact of including costs of added life ye‑
ars in economic evaluations. These two drugs 
are dabigatran and zytiga. In neither case the 
impact of including costs of added life years 
is presented in the decision made by TLV.
Dabigatran
Dabigatran is an oral direct thrombin inhibi‑
tor and the effect of the drug is predictable 
and does not need to be monitored but does 
not have any antidote. Dabigatran is an anti‑
coagulant drug which means that is prevents 
the blood from clotting. The drug is used to 
prevent stroke and thrombosis for adult pa‑
tients with atrial fibrillation.
To study whether dabigatran is a cost‑effec‑
tive drug a health economic evaluation was 
done [23] which was assessed by TLV. Here, 
dabigatran was compared to warfarin, in the 
aspect of the medical effects and costs. When 
putting together all effects and costs (inclu‑
ding certain assumptions requested by TLV), 
the cost per QALY gained was $77,089 [24]. 
The pharmaceutical was approved reimbur‑
sement.
As the size of the costs of the added life ye‑
ars are not presented, it was necessary to use 
the same model as TLV used. The model used 
indicates that 0.12 QALY and 0.09 life ye‑
ars are won when using dabigatran instead of 
warfarin and also the avoidance of stroke is 
0.05. When calculating the costs of added life 
years the current numbers [19] were used, 
updated with CPI to 2011 year values. In to‑
tal, including costs of added life years increa‑
sed the cost per QALY gained with $20,189, 
an increase with 35 percent.
After applying the re‑estimated costs of ad‑
ded life years (presented in Table II) that in‑
clude both informal production of 75 to 84 
year olds and increased formal production of 
65 to 74 year olds, multiplied with the CPI for 
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2011, the new cost per QALY for dabigatran 
becomes $64,538. This new cost per QALY 
is $12,551 less than the cost per QALY whe‑
re the present numbers were used. In Table 
III the costs per QALY for different scenarios 
can be seen.
Zytiga
Abirateron is the active substance of the drug 
zytiga. The drug makes the human body stop 
producing testosterone, which can lead to the 
growth process of prostate cancer slowing 
down. Zytiga is used to treat adult men who 
have prostate cancer and to those where the 
cancer has spread to other parts of the body.
In the case of Zytiga TLV declined its reim‑
bursement as the cost per QALY gained was 
too high ($167,147) [25]. No information 
about the costs of added life years was in‑
cluded in the decision. Later they presented 
information about their calculations in or‑
der to guide the county councils in Sweden 
[26], and it was then stated that an indirect 
cost has been added on these patients during 
survival and that these costs are production 
minus consumption, in other words, costs of 
added life years. These costs were calculated 
to be $8934 and increased the cost per QALY 
gained by $25,504 (an increase with 18 per‑
cent). These values cannot be updated with 
the recalculated numbers from Table II as the 
model used was not accessible.
COSTS OF ADDED LIFE 
YEARS AND ETHICS
There exist ethical complications when inclu‑
ding costs of added life years in health eco‑
nomic analyses. The guideline that TLV need 
to consider when making a foundation for the 
decision whether to reimburse a drug or not, 
is called the ethical platform [9]. The ethical 
platform consists of three principles, which 
are: the human value principle, the need and 
solidarity principle and the cost‑effectiveness 
principle. These principles should be priori‑
tized according to the above ordering, whe‑
re the cost‑effectiveness principle is the last 
principle that should be taken into account. 
The Dental and Pharmaceutical Benefits 
Dabigatran, 
base case
Dabigatran with 
re-estimated 
values of CAL
Zytiga
Cost/QALY without CAL 56,900 56,900 141,643
CAL 20,189 7,638 25,504
Total cost/QALY 77,089 64,538 167,147
Table III. The impact of costs of added life years on the cost per QALY of 
dabigatran and zytiga in US dollars (USD1 = SEK6.94)
CAL= Cost of added life years
Agency also has to make decisions according 
to the law of health and health care where 
in paragraph two it says that the goal for the 
health care system is good health and health 
care on the same terms for the whole popula‑
tion [27]. Also, health care should be given 
with respect to the equal value of each indi‑
vidual and with respect to every individual’s 
dignity. The individual with the greatest need 
for health care should be given priority. From 
these principles and laws it can be concluded 
that they stand in contrast to each other and 
following one principle means bending the 
other. This is true especially when taking into 
account costs of added life years in cost‑ef‑
fectiveness analyses where younger are prio‑
ritized over the elderly. Because the inclusion 
of costs of added life years does discriminate 
the elderly it can be viewed from the point 
of the fair innings principle [28]. The reason 
why is because the elderly have already had 
the chance to live their life, had their fair in‑
nings, and therefore the younger population 
should be prioritized. By including an addi‑
tional cost, the net consumption that is posi‑
tive for the elderly due to less production on 
the cost‑side in the analysis, maybe a more 
rightful result will appear according to the 
fair innings principle.
DISCUSSION
The guidelines that TLV applies in their he‑
alth economics evaluations came to place in 
2003 meaning they have ten years of expe‑
rience in including costs of added life years 
in analyses. Even though these costs have 
been included in analyses for a decade not 
many were aware of them until the beginning 
of 2013 when TLV explicitly wrote that sur‑
vival of patients with prostate cancer increa‑
sed societal consumption but not production. 
This was presented in the information about 
the health economic calculations of zytiga 
[26], which was not accepted for reimburse‑
ment, and it was the start for a public discus‑
sion. One reason behind the previous lack of 
discussions about the inclusion of costs of 
added life years was that very few understo‑
od how the calculations of costs of added life 
years were computed as well as not under‑
standing the impact of including these costs.
There are strong theoretical arguments for the 
inclusion of costs of added life years but the 
decision whether to include or exclude these 
costs should partly be based on the perspec‑
tive that the society chooses to have when al‑
locating health care resources. If the society 
chooses to have a societal perspective, as is 
the case in Sweden and many other countri‑
es around the world, all costs and benefits 
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should be included in an analysis according 
to the interpretation of a societal perspective. 
In spite of this, Sweden is the only country 
where it is recommended to include costs of 
added life years in health economic evalua‑
tions. The main reason for this, together with 
other aspects, is probably the ethical conse‑
quences that the inclusion would give rise to 
as well as the difficulty to disentangle related 
and unrelated costs. This difficulty to disen‑
tangle related and unrelated costs is the rea‑
son why there is a discussion about whether 
to include or not include dialysis in the CEA 
for patients with chronic kidney disease [18]. 
According to the article the inclusion of the 
costs of dialysis will lead to the treatment not 
being cost‑effective and leading to a negative 
decision on reimbursement.
The inclusion of costs of added life years be‑
comes even clearer when having a welfarist 
background. As Johannesson and Meltzer 
[29] stated, these costs are real costs and 
excluding them would lead to a bias. The 
cost‑effectiveness analysis, with the costs of 
added life years included, would then be an 
independent analysis of the cost‑effectiveness 
of a drug or an intervention and should be 
separated from the ethical platform that also 
need to be considered. Then, after knowing 
that all the costs are accounted for and seeing 
how large the cost‑effectiveness ratio is, the 
human value principle and the need and soli‑
darity principle could be applied and thereaf‑
ter a decision could be made knowing that all 
the aspects would be taken into account.
If choosing to have a societal perspective and 
including cost of added life years, the esti‑
mates used for these costs should be re‑esti‑
mated and updated. The present estimates 
used in Sweden are from one year only, 1997 
[19], and the consumption and production 
has changed since then. Informal production 
is a factor that is completely missing from 
the estimates of production, most probably 
due to the difficulty in giving a value to in‑
formal production. An additional aspect that 
needs attention is the inclusion of variation 
in the estimates of costs of added life years. 
There is uncertainty and a wide spread in the 
production and consumption for 65 year olds 
where some could work several more years 
and others are retired and thereby overesti‑
mating or underestimating the costs of added 
life years for individuals. Furthermore, pa‑
tients surviving a mortal disease rarely repre‑
sent the average population and neither pro‑
duce or consume as average. Additionally, in 
many cost‑effectiveness analyses, a simula‑
tion model are used which follow the patients 
for the rest of their life. In these cases it is 
common to include health care costs related 
to the certain health states and if the costs of 
added life years from Table I are added this 
would lead to double counting of these costs. 
Another drawback of the current estimates 
of costs of added life years is the fact that 
CPI is added to them in order to upgrade the 
numbers to today’s date but consumption of 
different goods or services could have increa‑
sed faster or slower than CPI. All these exam‑
ples above show that the current estimates of 
costs of added life years need to be updated 
and re‑estimated.
In order to show the impact of the inclusion 
of costs of added life years on an analysis two 
cases with two different drugs were presen‑
ted, dabigatran and zytiga. In both cases the 
costs of added life years increased the cost 
per QALY gained substantially (35% and 
18%). Using updated numbers of produc‑
tion in the case of dabigatran the incremental 
cost‑effectiveness ratio was approximately 
$12,551 less.
In Sweden, TLV does not have a threshold 
value for the cost per QALY but some 
“cut‑offs” can be seen from previous deci‑
sions as well as by the guidelines from the 
National Board of Health and Welfare in 
Sweden (Socialstyrelsen) [30]. In general the 
threshold seems to be somewhere between 
SEK 500,000 ($72,000) and SEK 1000,000 
($145,000), depending on the need of the 
patient group. For both the presented drugs 
in this study, the inclusion of costs of added 
life years led to the drugs passing these levels 
(dabigatran for the lower and zytiga by the 
upper). Whether the costs of added life years 
had any impact on the decision is however 
not possible to analyze. These two examples 
show how large of an impact cost of added 
life years has on the analysis and also impli‑
cates that because of this impact it is impor‑
tant that these estimates are truthful and well 
thought‑out.
Several ethical viewpoints are in line with the 
inclusion as well as the exclusion of costs of 
added life years. First of all, the principles 
that TLV need to consider when making deci‑
sions about reimbursement stand in contrast 
to each other. In the law of health and health 
care it is specifically stated that the goal of the 
health care system should be good health and 
health care on the same terms for the whole 
population [27]. This goal is contradictory to 
the principle of cost‑effectiveness when costs 
of added life years are included, health care 
will not be allocated based on the same terms 
because individuals are divided according to 
age. The concept of fair innings can be seen 
as standing in line with the inclusion of these 
costs and the studies on the general popula‑
tion stand in line with the inclusion as well.
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CONCLUSIONS
There is strong theoretical support for the 
inclusion of costs of added life years if a so‑
cietal perspective is applied, as is the case in 
Sweden. The examples used in this article, 
dabigatran and zytiga, have shown that there 
is a significant impact on the analysis when 
making decisions on reimbursement when in‑
cluding costs of added life years. Due to the 
fact that the inclusion of costs of added life 
years has an impact the estimates used must 
be as truthful as possible. As seen, after criti‑
cally analyzing the present estimates of costs 
of added life years, it is necessary to make 
improvements to these estimates that are used 
by TLV. There are different ethical views that 
support the inclusion of costs of added life ye‑
ars as well as ethical views that do not support 
the inclusion. However, the inclusion of costs 
of added life years clearly contradicts the ethi‑
cal principle of human value that is included 
in the law of health and health care in Sweden.
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